Viral fitness cost prevents HIV-1 from evading dolutegravir drug pressure

Abstract excerpt

BACKGROUND: Clinical studies have shown that integrase strand transfer inhibitors can be used to treat HIV-1 infection. Although the first-generation integrase inhibitors are susceptible to the emergence of resistance mutations that impair their efficacy in therapy, such resistance has not been identified to date in drug-naïve patients who have been treated with the second-generation inhibitor dolutegravir....

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to HIV/AIDS drug development and treatment
• Share to HIV/AIDS Research and Interventions
• Share to HIV Research and Treatment